AmerisourceBergen (ABC) and Good Neighbor Pharmacy (GNP) are committed to advocacy with legislative and regulatory bodies to ensure independent community pharmacists can continue to do what you do best, providing quality patient care in the vitally important community setting. We value our partnership with you.
ABC and GNP are also committed to fair, accurate, and timely reimbursement for pharmacy partners. Delays or uncertainty in payments destabilizes the viability of pharmacies and patient access to life-saving medications. So called “Direct and Indirect Remuneration” (DIR) fees that are imposed by PBMs retroactively make it difficult for pharmacies to determine the actual reimbursement at the time of dispensing. That is why ABC and GNP support greater transparency on DIR fees and having them assessed at point of sale rather than retroactively.
Please take a few minutes to visit NCPA’s website to comment on a few pharmacy-friendly provisions
included in the Centers for Medicare and Medicaid Services recent Medicare Part D Proposed Rule, especially the request for information re the notion of DIR fees being assessed at point of sale rather than retroactively. Below is an update and action alert from NCPA regarding next steps to advocate for your community pharmacy and your Medicare patients.
From NCPA: Urge CMS to Adopt DIR POS Proposal
- First, please take a moment and submit a public comment supporting the DIR proposal and other pharmacy-friendly provisions of the proposed rule, and encourage CMS to finalize that language. Click here to submit a comment before the Jan. 16 deadline. Please personalize the message with your own experiences.
- Second, there is also a bipartisan letter circulating in Congress voicing support for CMS moving forward with its pharmacy DIR proposal. Please click here to email your legislators and urge them to sign on to this letter.
- Finally, NCPA will also be submitting comments to CMS. If you are a pharmacy owner/manager, please take a few moments to complete a brief survey and let NCPA know how DIR fees are impacting you and your patients. Your input will help guide NCPA’s comments.